Most children with asthma have their disease easily controlled if low-dose inhaled corticosteroids (ICSs) are regularly and correctly administered. If a child presents with asthma which is apparently resistant to therapy with high-dose ICS and other controllers, then they have problematic severe asthma. However, in light of the UK National Review of Asthma Deaths, definitions of severe asthma based solely on the levels of prescribed treatment are too narrow. A detailed assessment of all such children should be performed. First, the diagnosis of asthma should be confirmed, then co-morbidities assessed. Next, a nurse-led assessment further characterizes the problem, conventionally categorizing the child as either having difficult asthma or severe therapy-resistant asthma. Here, we reassess in particular the interactions between, and management of, these two categories, highlighting that this dichotomous classification may need reconsideration. We use bronchoscopy and an intramuscular steroid injection to determine if the child has steroid-resistant asthma, using a novel, multidomain approach because the adult definition does not apply to around half the children we see. Finally, we highlight some mechanistic data which have emerged from this protocol such as the absence of T-helper 2 (TH2) cytokines even in eosinophilic severe asthma and the potential role of the innate epithelial cytokine IL-33, novel data on lineage negative innate lymphoid cells, which we can measure in induced sputum, and demonstrating that intraepithelial neutrophils are associated with better, not worse asthma outcomes. Severe paediatric asthma is very different from severe asthma in adults, and approaches must not be uncritically extrapolated from adult disease to children.
INTRODUCTION
The model of problematic severe asthma 1,2 as a referral umbrella term has stood us in good stead (Fig. 1) . When attempting to sort out the child referred with 'nightmare asthma', the first consideration is to ensure if the diagnosis of asthma is in fact correct; few children with symptoms due to an endobronchial foreign body have been improved by high-dose inhaled corticosteroids (ICSs). The next conventional step is to explore whether there are co-morbidities, and then, as a result of a detailed multidisciplinary assessment, assign the child as either having 'difficult asthma' (DA) or 'severe, therapy-resistant asthma' (STRA). [1] [2] [3] [4] This approach has the great merit of dissecting out a group (STRA) for whom detailed phenotyping and a personalized medicine approach is fully justified because who is really interested in the pathology of the airway in children who would likely respond well to ICS if given regularly and administered correctly or who could justify administering a novel biological to them either? However, the needs of the clinician, as opposed to the clinical scientist, may require a reappraisal of this approach; the first priority of the clinician is to keep the child alive and (preferably also) with controlled asthma, even though the family may not deal with adverse environmental factors or ensure treatment is administered regularly and correctly. We have previously reviewed our approach to really severe asthma [4] [5] [6] ; the purpose of the current review is to update our experience over the last 6 years, also in light of the findings of the National Review of Asthma Deaths (NRAD 7 ). We previously showed that many children who have been identified as having DA are able to reduce prescribed treatment (which in practice may mean increasing administered treatment) while having improved outcomes 8 ; however, perhaps this has resulted in us underestimating the really serious problems that DA may pose; so, for example, identification of non-adherence as the problem does not inevitably mean that a solution will be found. Children with DA may not be amenable to the latest pharmacological monoclonal wizardry, but nonetheless DA poses a threat to health and life. Perhaps, beyond guidelines therapy has two, not one indication. These would be STRA and also DA refractory to interventions (discussed in more detail below), if only to try to keep these children alive despite the best efforts of some families (and sometimes themselves). So, one intention of the current review is to develop our thinking about children referred to specialist care with uncontrolled respiratory symptoms. It should be stressed from the outset that this sort of assessment is impossible without a skilled multidisciplinary team (Table 1) . 9 Furthermore, a new framework initially proposed for the assessment of COPD is extremely helpful in the management of airway disease (Fig. 2) . 10 Complementary approaches have been used to describe the complexities of asthma. 11, 12 This reminds us that, since most children with asthma respond to low-dose ICS if administered regularly and efficiently, the clue to apparent non-response likely lies outside the airway, in the realms of co-morbidities and social and environmental factors, rather than due to atypical airway pathology. Indeed, only around 10% of our referrals have such atypical pathology (or STRA). Incidentally, the converse is true in preschool wheeze, not discussed in detail here, where our pharmacological options for treating airway disease are so limited. In addition to updating our approach to severe asthma, we will discuss recent work from our group on the pathophysiology of paediatric STRA, specifically with reference to how this differs from adult disease.
NOT ASTHMA AT ALL: WRONG DIAGNOSIS
There have been no major breakthroughs in this field, merely the ongoing depressing cycles of failure. Without question, asthma was underdiagnosed in children 30 years ago, to the detriment of asthmatic children. However, we have now fallen neatly into the opposite trap; the train of reasoning now is, if you think it may possibly be asthma, it IS asthma, you do not need to do any further testing, least of all (perish the thought) any objective testing, and if you do not immediately prescribe ICS in ever increasing doses, you are a BAD DOCTOR. Even worse, a diagnosis of 'possible asthma' is given, which gradually and with no evidence becomes by force of repetition a definitive diagnosis, with prolonged treatment being given. Dare we suggest that this scenario suits the big pharmaceutical companies' agenda to a tee? In the UK, the National Institute for Clinical Excellence (NICE) had the temerity to propose that an asthma diagnosis should be underpinned by objective testing 13 ; howls of rage greeted this suggestion in some circles, despite overwhelming evidence that overdiagnosis of asthma is a huge problem both in primary and secondary care.
14-16 Indeed, we were pilloried for suggesting that asthma was overdiagnosed and asthma inhalers had become almost a fashion accessory. 17 So, perhaps the term 'problematic severe asthma', useful as it has proved, might better be replaced with the term 'problematic respiratory symptoms unresponsive to prescribed asthma therapy'.
So, the first issues on receiving a referral of a child with an asthma diagnosis, and who has problematic respiratory symptoms is, what is the evidence that this child has an airway disease of any sort, let alone asthma? And if an airway disease is present, what are the components 18 ? As always, the first step is to go right back to square one, and take a really focused history and perform a thorough physical examination. Does the child have any or all of cough, wheeze and breathlessness? Isolated dry cough in an otherwise well child is highly unlikely to betoken a significant disease. 19 The term wheeze is often applied to many different sounds. [20] [21] [22] [23] Breathlessness is universal if sufficiently intense exercise is undertaken. In this context, it is opportune to remember that only about half of those complaining of exercise-induced breathlessness have a formal diagnosis of asthma or exercise-induced laryngeal obstruction (EILO) 24 ; the rest (who were not more obese) were just deconditioned or consciously or unconsciously exaggerating their symptoms. Symptoms should not be taken at face value. If there is any doubt, an exercise test should be ordered, to determine exactly what the problem actually is; being overweight and deconditioned will not be helped by β-2 agonists or ICS! If there are persistent symptoms with normal spirometry, and doubts as to whether these are real, a methacholine challenge may be enlightening; although airway hyper-responsiveness is seen in normal people, absence of methacholine hyperresponsiveness is never seen in uncontrolled symptomatic asthma.
Elsewhere, 25, 26 we have argued in detail that the term 'asthma' is an umbrella of dubious provenance, the components of which should be unpicked in nonstraightforward cases of airway disease; in this context, fixed and variable airflow obstruction, and inflammation and infection (Table 2 ). So at this stage, the evidence should be reviewed and the gaps plugged to determine what actually is going on in the airways of the child. It is to be hoped that atopic status has previously been determined; although non-atopic paediatric severe asthma indubitably exists, it is rare, and the absence of atopy should prompt a very full diagnostic review. Assuming that the child really has asthma, a detailed, nurse-led, multidisciplinary assessment is the next step (Fig. 2) . The Venn diagram is a departure from previous approaches, and the reasoning is given below.
A NEW VENN DIAGRAM-WHY?
Although the division between asthma plus, DA and STRA is useful, the individual child may sometimes not fit neatly into a single box. So, for example, a child with DA may die in an acute attack, clearly a very severe outcome, and thus merits as much energy and attention as the child with STRA; a child with STRA may be obese, and the pro-inflammatory effects of obesity may be targeting the airway and driving steroid resistance (described below); and the child with Table 2 Interpretation of apparent associations between asthma and co-morbidities
• Asthma causes the associated disease (obesity secondary to steroid therapy and exercise intolerance) • The associated disease causes asthma (obesity asthma phenotype) • Both are caused or aggravated by some underlying factor (stress causing asthma and EILO) • The association is coincidental, and has resulted from Berkson's bias • The diagnosis of asthma is incorrect, and the physician has been misled by the co-morbid conditions (EILO and obesity) EILO, exercise-induced laryngeal obstruction. both asthma and EILO may have stopped taking asthma treatment because of failure to prevent EILO (misinterpreted by the child as severe asthma). Hence, we suggest a modification in our current approach ( Fig. 3 ) to recognize that a strict categorization may not always be possible because of overlaps, and at least in some cases a more complex formulation may be needed.
ASTHMA PLUS: WHAT DOES IT MEAN AND WHAT IS ACTUALLY IMPORTANT?
Associations between diseases may be real or apparent (Table 2) . Causation can only be determined by intervention studies, the clearest demonstration being with gastro-oesophageal reflux (GOR, described below).
Exercise-induced laryngeal obstruction
This commonly coexists with asthma, and is due to inappropriate closure of the larynx during exercise. Symptoms usually occur during rather than at the end of exercise, are unresponsive to short-acting β-2 agonists and are usually predominantly of inspiratory difficulties, three features significantly aiding differentiation of EILO from exercise-induced bronchoconstriction. Underlying causes should be considered:
• No structural abnormality, psychological factors predominate
• Structural laryngeal disorder-previous laryngomalacia, 27 recurrent laryngeal nerve palsy 28 • Indeterminate pathology The diagnosis should be suspected on the history, focusing on the three factors listed above. A video of an attack showing acute stridor rather than wheeze is helpful confirmatory evidence. If doubt remains, direct laryngoscopy is performed during exercise, 29 so the young person can see the abnormal laryngeal movement for him or herself. Treatment depends on the underlying cause; key is to acknowledge that the symptoms are genuinely distressing, but are not of asthmatic origin, and will not respond to asthma medications. Intervention by a respiratory physiotherapist, speech and language therapist, or a clinical or sports psychologist may resolve the problem. In selected cases, surgery may be helpful.
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Obesity
This is an area where new and highly relevant data have impacted our thinking about STRA (Table 3) . Clearly, deconditioning in obesity may lead to an erroneous diagnosis of asthma, and obesity and deconditioning merit treatment in their own right, irrespective of any airway disease. The International Study of Asthma and Allergies in Childhood (ISAAC) showed an increased prevalence of asthma in overweight and obese children; there was no association with atopy, 34 implying either that asthma in obesity is a different disease from usual school age atopic asthma (which is also suggested by the pattern of symptom reporting 35 ), or that the association was spurious. The fact that obesity was associated with a greater likelihood of admission to hospital and paediatric intensive care unit (PICU) suggests the former was the case, 36 and indeed there is some evidence that obesity is associated with steroid resistance. 37 However, associations may be confounded by the association of obesity with low socioeconomic status, 36 bringing with it passive smoke exposure and the effects of neighbourhood deprivation amongst others, 38 so as always, there should be caution in interpreting association studies.
Given that the balance of evidence is that obesity asthma is real, and different from lean, school age atopic asthma, what is its phenotype? We have used the above-described scheme which deconstructs the airway. In terms of fixed airflow obstruction, an obesity-specific mechanism has recently been proposed, namely dysynaptic lung growth. 39 This is 40 and excessive weight gain in the first year of life 41 are associated with poorer lung function, although whether this is via dysanapsis or another mechanism is unclear. The mechanisms of variable airflow obstruction include not only bronchial hyperresponsiveness, but also the effects of atelectasis secondary to obesity; reversal of atelectasis by, for example, sighs or the big breaths of exercise may provide another mechanism of reversible airflow obstruction which is unrelated to β-receptor activity.
The data on eosinophilic inflammation are conflicting, with studies suggesting that airway eosinophilia is either important 42 or not present. 43 Obesity is known to be associated with inflammatory phenotypes which vary developmentally and with gender. 44 Recently, the novel hypothesis that the airway may be the target of systemic inflammation has been proposed. 45 In a study of two adult cohorts comprising more than 600 patients, asthma outcomes were related to serum IL-6 (a marker of systemic inflammation). A total of 111/138 of the IL-6 high asthmatic patients were obese, but 178/289 of obese asthma patients were IL-6 low. The authors concluded that metabolic dysfunction was not exclusive to the obese asthmatic patients, but IL-6 high asthmatic patients had worse outcomes, not mediated via type 2 inflammation. In practical terms, this suggests that the inflammatory phenotype in obese asthma is variable between individuals, and should be determined on a case by case basis. For sure, before ICS are escalated, every effort should be made to ensure that residual type 2 inflammation is really present, possibly using induced sputum, peripheral blood eosinophil count or exhaled nitric oxide.
There are number of different papers linking 'obesity and obstructive sleep apnoea (OSA)', 'OSA and asthma' and 'OSA and systemic inflammation'. [46] [47] [48] [49] [50] The practical consequence is that OSA should be excluded in DA and STRA (testing depending on the level of suspicion), and treated if present on its merits. Whether treatment of OSA will be beneficial to asthma control will likely vary between individual patients.
The importance of the microbiome in normal immunological development, the inception of asthma and in established asthma, is well established. [51] [52] [53] There is also evidence that obesity has significant effects on the microbiome. 54 However, data on the microbiome in the obese, and airway disease, are scant and an area for future research. Airway disease in the obese has recently been reviewed in more detail. 55 The immediate response to the obese asthmatic patient is, if you lose weight you will get better, just do it. And indeed, bariatric surgery improves asthma control at least in adults. 56 In one study comparing three groups (obese asthma and bariatric surgery (n = 27), bariatric surgery in the non-asthmatic (n = 39) and obese asthma not treated with bariatric surgery (n = 12)) in a non-randomized design, those who had bariatric surgery lost weight, and improved FEV 1 and small airway function (especially if they had been diagnosed with asthma), and those asthmatic patients who underwent bariatric surgery had improved Airway hyper-responsiveness (AHR; however, in terms of inflammation, there were only minor reductions in airway mast cells in this group, and no other inflammatory consequence. We also know that obese children with OSA who lose weight improve their symptoms. Obviously, weight loss is important for respiratory as well as non-respiratory reasons, but if obesity leads to structural changes (described above) we should not assume that weight loss will solve all the problems.
In summary, those who are obese should try to lose weight, irrespective of any upper or lower airway disease. If this is not achievable, or while this is happening, it is critical objectively to assess airway disease (Table 2) . In particular, it should be determined whether there genuinely is an airway disease, and an exercise test may be illuminating, and also, whether there is uncontrolled type 2 inflammation, before steroid therapy is escalated.
Rhinosinusitis
Symptoms are sufficiently debilitating as to merit treatment irrespective of any benefit on asthma control. 57 There is, however, evidence that treatment of rhinosinusitis will also improve asthma control as a bonus. 58 Discussion of potential mechanisms is beyond the scope of this article; for us, the key question is, 'does it work?' rather than 'should it work?' and on that basis treatment should be offered.
Food allergy
There is a higher than expected prevalence of food allergy in asthmatic children admitted to PICU. 59 The direction of the relationship is unclear. It may be difficult to determine whether exercise-induced symptoms or acute deterioration is related to asthma or anaphylaxis. Our practice is to treat both on their merits, and err on the side of caution in asthma treatment.
Gastro-oesophageal reflux
There is no doubt that GOR frequently coexists with asthma in children, but equally no doubt that treatment of GOR, irrespective of whether the child has symptoms or not, is wholly ineffective in improving asthma control. 60 GOR is not a co-morbidity of severe asthma, even in obese children.
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THE NEXT STEP-THE MULTIDISCIPLINARY TEAM ASSESSMENT
There is no possibility of running a successful severe asthma clinic without an excellent multidisciplinary team ( Table 1) . Details of the assessments are described elsewhere, 2-6 and we are happy to share our severe asthma protocols. Here, we highlight recent developments in this process. The initial assessment is as an outpatient, including a home visit and making contact with the school; an inpatient admission may also be illuminating (described below).
Adherence
Increasingly, sophisticated methods are being used to determine whether children are taking medication regularly and correctly. Although prescription uptake is still useful, electronic monitoring is an essential part of the assessment (Table 4) . History taking and questionnaires are not useful in our hands. We assess asthma control (Asthma Control Test score), spirometry and exhaled nitric oxide before and after monitoring. Even electronic monitoring does not prove the medication was correctly inhaled, and the addition of an audio signal reveals that actual adherence is less than that determined by simple electronic signals. 62 Managing non-adherence remains one of the biggest challenges of the severe asthma clinic. If all else fails, consideration should be given to directly observed therapy (described below).
Allergen avoidance
The combination of allergen sensitization, allergen exposure and respiratory viral infection is strongly predictive of hospitalization with an asthma attack. 63 Of these, only allergen exposure is amenable to intervention, and skin prick tests and specific IgE are used to determine sensitization. 64 Exposure to many aeroallergens is inevitable, but furry pets are an obvious example of what can and should be avoided.
Nicotine exposure
This may be through passive or active exposure to tobacco or increasingly e-cigarettes, and is detected by urinary or salivary cotinine measurements. There is increasing evidence in adults and children that tobacco exposure, either active or passive, leads to steroid resistance.
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Psychosocial morbidity
Anxiety and depression are common, as are issues arising from poor school attendance. 67 We are increasingly aware of safeguarding concerns in many of our children 68 These include exaggeration of symptoms, sometimes for financial gain. If there is a disconnection between symptom reports and objective findings, then a school visit may be helpful; teachers are shrewd observers, and if no symptoms are seen on the sports field or elsewhere at school, then exaggeration for whatever reason is likely. The report of multiple courses of oral prednisolone for severe asthma attacks should not necessarily be accepted uncritically. Unfortunately, all too many 'attacks' are treated without recourse to any objective measure of severity, and even when these are made, they may be ignored because of a perception that this is really severe asthma. We have seen a child treated with i.v. salbutamol while having an oxygen saturation of 100% in air; the 'asthma attack' was in fact hyperventilation. The links between the airway and brain are complex and bidirectional. [69] [70] [71] There is evidence from human and animal studies that stressful events worsen airway inflammation, and that airway inflammation can influence central events, possibly via the vagal and non-adrenergic, non-cholinergic nervous systems. There is also evidence that psychological stress may have epigenetic effects. 72 Life stress events in adolescence have varying effects including worsening of preexisting asthma and perhaps inducing new cases of incident asthma. 73, 74 When dealing with a child with asthma and psychosocial issues, trying to determine whether asthma caused the psychosocial issues, or the psychosocial issues caused the asthma is a futile exercise. The presence of both must be acknowledged, and both should be addressed, without attempting to unravel causality.
DA: WHAT DO WE DO?
As discussed, the identification of reversible factors such as poor adherence is not the same thing as correcting them. Despite everything, adherence may be poor, psychosocial factors insoluble and the home environment remains polluted and chaotic. To walk away cannot be the right response, but there is little evidence to guide the paediatrician. We suggest the following:
• Adherence-if despite psychology input and simplifying the regime to the bare bones, this remains poor, consideration should be given to directly observed therapy at school, considering also the use of a once daily ICS-long-acting β-2 agonist combination • The issue may sometimes be a disconnection between symptom perception and physiological reality. An admission to hospital, with directly observed therapy to resolve the issue of adherence, may be Severe asthma in children helpful. Short-acting β-2 agonists are only administered after a medical assessment, not on demand.
We monitor reversible airflow obstruction and fractional exhaled nitric oxide (FeNO), and if they improve in hospital with directly observed therapy it means that there are either or both of (i) nonadherence or (ii) a pro-inflammatory drive in the home environment. A vigorous exercise programme supervised by the physiotherapist is part of the admission, and children often surprise themselves with what they can actually do • Allergen avoidance is preferable to injections every 2-4 weeks, but if the family will not exclude pets, or minimize allergen exposure by washing the cat regularly, should the child be penalized? Perhaps under those circumstances, omalizumab therapy is justified • Finally, and as a last resort, referral to child safeguarding (i.e. child protection services) must be considered, and is an increasing issue in our clinic. This sounds Draconian-but asthma is a killing disease if prescribed treatment is not taken It should also be noted that patients initially thought to have reversible factors may in fact have STRA. Thus, poor adherence may be due to lack of therapeutic efficacy, hence the child has stopped taking treatment. Reinstituting therapy may confirm it is ineffective, and move the child into the STRA category and further invasive assessment.
INVASIVE ASSESSMENT OF STRA
The next step for the STRA child is bronchoscopy and a steroid trial with parenteral triamcinolone. The aim is to answer the following questions, and thus develop an individualized treatment plan.
• Does the child have fixed airflow obstruction? Again, there is no point in escalating treatment to try to reverse the irreversible • Is there dissociation between inflammation and symptoms 75 ?
• What is the pattern of airway inflammation (if any)?
There seems little logic in giving ever more potent anti-inflammatory agents if the airway is not inflamed • Is the child steroid responsive?
Although the questions are easily comprehensible, the lack of evidence not only makes answering some of them difficult, but also highlights the differences between adults and children with STRA.
There is no uniformly accepted definition of fixed airflow limitation in children. An FEV 1 which never rises above 1.96 Z-scores clearly betokens fixed obstruction, but neither the dose, duration and route of a systemic steroid trial, nor the dose and route of bronchodilators which should be used to maximize airway function is agreed. Our single dose triamcinolone regime at least has the merit of ensuring adherence, which an oral trial does not. However, there is evidence that neither a 2-week course of prednisolone 76 nor a single dose of triamcinolone, 77 with post-trial 1 mg salbutamol administered using a large volume spacer may not predict target lung function in the following year. It is likely that steroid responsiveness is not 'all-or-none', but a spectrum and many apparently unresponsive may respond to huge, prolonged steroid doses; however, such doses would be impractical for clinical purposes. The question of steroid responsiveness in children is discussed below in more detail.
The importance of discordant phenotypes (inflammation, no symptoms and symptoms, no inflammation) was first highlighted in adults. 75 The extent to which this is an issue in paediatric STRA is unclear, but the principles apply across the age range. Symptoms, particularly in the obese, should not lead to uncritical escalation in therapy; rather the underlying cause should be determined. Our practice (not evidencebased) would be to intensify anti-inflammatory treatment in the child with severe asthma attacks, minimal interval symptoms, but underlying eosinophilic airway inflammation. We need to move towards direct monitoring of what we are treating, rather than using guesswork.
In terms of treatment options, these have been reviewed elsewhere. 5, 78 Omalizumab is reserved for children who have been through a detailed assessment as described above. Preliminary data suggesting how responders may be selected and the possible role of novel anti-type 2 inflammation monoclonals are discussed below.
SAFS: potential approaches
There are no agreed criteria for paediatric severe asthma with fungal sensitization (SAFS), and we have modified the adult ones ( Table 5 ), reflecting that, unlike in adults, allergic bronchopulmonary aspergillosis is rare if ever seen in children with asthma. We have shown that these children have evidence of worse inflammation than STRA without SAFS, despite being prescribed more treatment. 79 The innate epithelial cytokine is increased in bronchoalveolar lavage (BAL), and immunohistochemistry of bronchial biopsies also show increased IL-33-positive cells in children with SAFS, and in a neonatal Alternaria-sensitized murine model. Management is avoidance of fungal exposure as far as possible (checking any nebulizer for contamination and avoiding stables) and consideration of antifungal therapy, although it has to be said that the evidence for antifungal therapy is not compelling. 80, 81 If itraconazole is used, the potential interaction with budesonide which can lead to iatrogenic Cushing's syndrome should be remembered.
LONG TERM: AFTER THE ASSESSMENT
The assessment of STRA and DA cannot be considered a definitive 'one-off'. These children need regular and detailed follow-up, and probably at least a formal annual review, in which at the very least adherence is objectively reassessed, together with allergen sensitization and exposure. Adherence in particular fluctuates over time, and strategies to support adherence may also need to change.
SIMILARITIES AND DIFFERENCES BETWEEN ADULT AND PAEDIATRIC STRA
Role of type 2 cytokines
The adult asthma paradigm of eosinophilic airway inflammation driven by type 2 cytokines has culminated in the successful deployment of a number of monoclonals directed against this pathway.
82-84 However, the evidence that type 2 cytokines are important in paediatric severe asthma is less compelling. Very few adolescents have been included in many of these studies (ID Pavord, personal communication with permission). In our study, in which evidence of type 2 inflammation was sought in induced sputum supernatant, BAL (two different platforms) and immunohistochemistry of bronchial biopsies, evidence for the presence of IL-4, IL-5 and IL-13 was scanty. 85 The severe asthma research program (SARP) group 86 found that severe paediatric asthma was neither dominated by type 1 nor type 2 inflammation, rather the cytokines which distinguished severe asthma were GRO (growth related oncogene) (CXCL1), RANTES (regulated on activation, normal T cell expressed and secreted) (CCL5), IL-12, IFN-γ (interferon gamma) and IL-10. Clearly, the correct question with the new biologicals is not 'should they work?' but 'DO they work?' However, the lesson from these two papers is that mechanisms should not uncritically be extrapolated across the age range, and trial data are needed in children.
Role of innate epithelial cytokines
It seems that mechanisms other than type 2 cytokines are important, but their nature is unclear. Attention has focused on the innate epithelial derived cytokines IL-25, IL-33 and TSLP (thymic stromal lymphopoietin). 87 The potential role of IL-33 in SAFS has been discussed above. We have also shown that IL-33 promotes airway remodelling in children with STRA and also in a murine model, and is steroid resistant. 88 Furthermore, at physiological concentrations, Vitamin D induces the epithelial production of the decoy IL-33 receptor STR2, thus reducing IL-33 levels. Currently, there is no commercially available anti-IL-33 monoclonal, and clearly intervention studies are needed to determine whether this is a key pathway in children.
Role of lineage-negative ILCs
Innate lymphoid cells (ILCs) are characterized by their lymphoid morphology and absence of lymphocyte lineage surface markers. Group 2 ILCs expressing CD127 and CRTH2 are induced by the epithelial cytokines IL-33 and IL-25 and are implicated in the pathogenesis of allergic airway disease in murine models. Induced sputum from STRA children contained ILC2s expressing CD127 and CRTH2 but these were not found in control children with lower respiratory symptoms. 89 Total ILCs (Lin − CD45 + ) in sputum were 40 times higher suggesting that sputum from STRA children contains a significant number of Lin − CD45 + CD127 − cells. The proportion of T-helper 2 (TH2) cells (CD4 + CRTH2 + ) in sputum from STRA children was significantly greater than that of ILC2s. Strikingly, 10-fold more ILC2s were present in sputum than in peripheral blood from children with STRA, possibly because of preferential trafficking of ILCs to mucosal sites. There were no correlations between the proportions of ILC2s and the patients' clinical characteristics or demographic data and any clinical parameter. Importantly, the detection of ILCs in sputum gives an opportunity for future longitudinal studies of the role of these cells.
Assessment of steroid responsiveness
The conventional definition of steroid response in adults is a 15% or greater predicted increase in morning FEV 1 in patients with bronchodilator reversibility (BDR) of 12% or greater from baseline and an abnormal FEV 1 (<80% of predicted value) before a systemic steroid trial. 90 However, spirometry is a notoriously poor indicator of asthma severity in children, and many severe paediatric asthmatic children have a normal baseline FEV 1 . Indeed, the adult definition cannot be applied to around 50% of children with STRA. Furthermore, there is no agreed definition of the dose and duration of the steroid trial, and the dose of bronchodilators to assess response. We use a single intramuscular injection of triamcinolone to ensure adherence, followed by 1 mg salbutamol via a large volume spacer 4 weeks later. We have proposed a multidomain assessment of steroid resistance in children (Table 6) , 91 and used it to predict the response to the anti-IgE monoclonal antibody omalizumab. 92 Most children (approximately 70%) respond in some but not all domains; complete response and total nonresponsiveness are seen in around 15% each. Of note, 22 of 54 children had an elevated sputum eosinophil count after triamcinolone; steroid-resistant eosinophilic inflammation is a real entity in children, and is not all due to non-adherence. Our definition of steroid resistance should be considered a work in progress, but it seems logical, for example, to assess whether an antiinflammatory intervention affects airway inflammation, and not necessarily expect a physiological response.
The role of the neutrophil
Neutrophilic asthma is a well-recognized phenotype in adult asthma, which is notoriously steroid resistant and difficult to treat. 93, 94 In children with STRA, however, neutrophils were not found either in the submucosa or BAL fluid 85 ; indeed, their presence is suggestive of an alternative diagnosis. However, we recently reported that intraepithelial neutrophils are found in some children with STRA. 95 Challengingly, the neutrophil-HIGH children had better asthma outcomes (higher FEV 1 % predicted, correlating with intraepithelial neutrophil count, and a higher ACT) while being prescribed lower ICS doses. Tissue and luminal IL-17A was not increased, STRA children had increased submucosal and epithelial expression of IL-17R. Stimulation of bronchial epithelial cells with IL-17A led to steroidresistant IL-8 secretion.
These findings are striking and as yet unexplained; however, one is forced to the conclusion that the neutrophil is beneficial in some children with STRA. It is not clear whether neutrophil-HIGH and neutrophil-LOW children are completely different phenotypes, or if in fact they represent a differential response in the ability to mount a neutrophilic response to an adverse threat. In this context, it should be noted that the sputum neutrophil-high phenotype is not consistent in longitudinal studies. 96 In any case, the most obvious neutrophilic response which is beneficial is that to an infection. It is tempting to speculate that in at least some STRA children, low-grade bacterial infection is an important driver of symptoms. If this is true, whether this infection is a primary cause or secondary to airway surface immunosuppression by ICS 97 cannot be determined. We do know that there are differences in the airway microbiome between severe asthmatic patients and controls, 52 but again, whether primary or secondary cannot be determined; however, data from Ecuador shows that treatment-naïve wheezers have a different microbiome from non-wheezy controls. 98 These findings do however underscore that just because a cell is present it does not mean it is the cause of harm, and also drives home the lesson that adult and paediatric STRA may have important dissimilarities.
SUMMARY AND CONCLUSIONS
The most important part of managing problematic paediatric asthma is, and will remain for the foreseeable future, getting the basic rights. If this is achieved, many children will cease to have problems from asthma. DA with persistent non-adherence and STRA remain difficult issues to deal with, and a full multidisciplinary team effort is needed. Pathophysiologically, adult and paediatric STRA have some differences and may need different therapeutic approaches. There remains an urgent need for international collaboration to carry out randomized controlled trials of treatment in children with STRA.
